EP0644754A4 - Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes. - Google Patents
Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes.Info
- Publication number
- EP0644754A4 EP0644754A4 EP92901379A EP92901379A EP0644754A4 EP 0644754 A4 EP0644754 A4 EP 0644754A4 EP 92901379 A EP92901379 A EP 92901379A EP 92901379 A EP92901379 A EP 92901379A EP 0644754 A4 EP0644754 A4 EP 0644754A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bleeding
- powder
- surgery
- substance
- stop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Definitions
- P ⁇ TN ⁇ IK 1971 stated that the concentration of ascorbic acid has been reported as decrea ⁇ ingvith age in the rat eye lens, adrenal, brain, testis, and blood.
- Purpura (extensive bruising ) and hemorrhages under the tongue are common in elderly people. Tattersal and Seville 1950 reported purpura in 60 out of 009 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and fore- ornv. and on tr.e backs of their hands, noth p-it ientj.
- THIS invention pertains to the field of disorder of hem ⁇ stasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboe bolic disorders.
- the blood coagulation mechanism of ascorbic acid which - was administered topically does not fall into either intrinsic or extrinsic pathway cascade, since it works the same for hemosta ⁇ i ⁇ in normal situation as in chronic- hepatitis, colon cancer, and hemophilia patients in whom the coagulation factors 2, 7, 9, 10 in the liver dise and factor 8 or 9 in the hemophilia A or B cannot be produ
- the present methods available to stop bleeding in surger are cautery, epinephrine injection, pressure and some fiber foam.
- the cautery can cause tissue necrosis in some cases.
- the epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly >r* ⁇ ⁇ for diffuse capillary bleeding and any traditionally un ⁇ controllable bleeding tendency patients such as for patient with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency nf the kinds of aforementioned patients.
- the ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRN ⁇ in the regulation of collagen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
- Substance powder 001 represents ascorbic acid powder that i c obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding wnen spraying it topically on the bleeding area for any with the blood, the black tar gel like material is formed, and later becomes solid. The amount of the powder that is needed to react completely with the blood is proportional to the amount of the blood that comes out of the blood vessels. In rats, one capillary, one venous and one femoral artery bleeding were stanched within one second, if sufficien amounts of the powder of ascorbic acid were applied. The arte bleeding needs much more this powder of interest.
- test tube conditions it requires 0.1568 g of this substance powde to coagulate ( make the blood black and not move in the tube 1 ml of human blood in 6 minutes.
- This is the same for normal colon cancer a d hemophilia patients; 1 ml of normal blood needs 0.1568 g of ascorbic acid powder, 1 ml of colon cancer blood needs 0.1568 g of ascorbic acid powder, and 1 ml of hemophilia blood needs 0.1568 g of ascorbic acid powder.
- Suff substance powder 001 is particularly useful to help stop blee in the case of diffuse capillary oozing and mistakenly cut of artery or arteries that cannot be found during massive bleedi bleeding so as to save the patients' lives.
- the present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, press and some fiber foam.
- the cautery can cause tissue necrosis in some cases.
- the epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capillary oozi patients, while ascorbic acid powder does not cause any tissu necrosis and particularly works well for diffuse capillary bl and oozing and any traditionally uncontrollable bleeding tend patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients.
- the ascorbic acid also facilitate wound healing ( O Surg.
- the substance powder ool is made by grinding the pure vitamin C tablets into powder. Application of this powder topically to the bleeding area is betber'by spraying the powder topically on the bleeding area.
- the amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this * vitamin C powder to coagulate 1 ml of human blood. This ⁇ i ⁇ the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this s ⁇ tuation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows: (f) Rats Experiments
- Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off.
- Photograph # 1 massive bleeding when the femoral artery is cut off
- Photogrph # 2 bleeding stops within one second when sufficient powder of interest was poured topically into the bleeding area, in this case of massive active bleeding T did pouring instead of spraying.
- the amount of the powder needed is proportional to the amount of blood coming out of the vessel. It varies with the rats. Usually 0.1344 g is sufficient to stop bleeding for the femoral artery of the rat which is cut off vithin one second.
- the black tar gel like material was formed in one second as soon as the powder contacts with the blood .
- This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
- tube con il.ion as mentioned previously, ] m ] of human b 1 .nor! requires 0.15C>fl q of powder to form Ma ⁇ -k bloori coa- qulatton by shaking the tube with hand or ⁇ color machine.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62409490A | 1990-12-06 | 1990-12-06 | |
US624094 | 1990-12-06 | ||
PCT/US1991/009201 WO1992010999A1 (en) | 1990-12-06 | 1991-12-05 | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0644754A1 EP0644754A1 (en) | 1995-03-29 |
EP0644754A4 true EP0644754A4 (en) | 1995-12-27 |
Family
ID=24500629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92901379A Withdrawn EP0644754A4 (en) | 1990-12-06 | 1991-12-05 | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0644754A4 (en) |
AU (1) | AU662505B2 (en) |
CA (1) | CA2095439C (en) |
NO (1) | NO930858D0 (en) |
WO (1) | WO1992010999A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2336925A1 (en) * | 1975-12-30 | 1977-07-29 | Mouney Guy | Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc. |
DE2808572A1 (en) * | 1977-03-04 | 1978-09-07 | Shiraimatsu Shinyaku Co | HAEMOSTATIC AGENT |
WO1987006465A1 (en) * | 1986-04-22 | 1987-11-05 | Olav Johan Braenden | Anti-cold kit, anti-cold preparation and use thereof |
WO1990012572A1 (en) * | 1989-04-17 | 1990-11-01 | Duke University | Stable ascorbic acid compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1334933A (en) * | 1971-02-19 | 1973-10-24 | Ahrens G W | Reaction products of caldium ascorbate and preparation containing them |
US4959362A (en) * | 1983-12-19 | 1990-09-25 | Takeda Chemical Industries, Inc. | Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system |
US5021452A (en) * | 1989-01-09 | 1991-06-04 | The Board Of Regents Of The University Of Washington | Process for enhancing wound healing |
-
1991
- 1991-12-05 CA CA 2095439 patent/CA2095439C/en not_active Expired - Fee Related
- 1991-12-05 WO PCT/US1991/009201 patent/WO1992010999A1/en not_active Application Discontinuation
- 1991-12-05 EP EP92901379A patent/EP0644754A4/en not_active Withdrawn
- 1991-12-05 AU AU91034/91A patent/AU662505B2/en not_active Ceased
-
1993
- 1993-03-09 NO NO1993930858A patent/NO930858D0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2336925A1 (en) * | 1975-12-30 | 1977-07-29 | Mouney Guy | Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc. |
DE2808572A1 (en) * | 1977-03-04 | 1978-09-07 | Shiraimatsu Shinyaku Co | HAEMOSTATIC AGENT |
WO1987006465A1 (en) * | 1986-04-22 | 1987-11-05 | Olav Johan Braenden | Anti-cold kit, anti-cold preparation and use thereof |
WO1990012572A1 (en) * | 1989-04-17 | 1990-11-01 | Duke University | Stable ascorbic acid compositions |
Non-Patent Citations (4)
Title |
---|
ANTOSZEWSKI Z: "Zastosowanie preparatu Cepevit-K do tamowania krwawien i krwotokow po usunieciu zebow.", POL TYG LEK (POLAND), NOV 20 1972, VOL. 27, NO. 47, PAGE(S) 1861-2, * |
DATABASE MEDLINE GURNEY B.F.: "Hemostatic Agents" * |
ORAL HYG., vol. 56, no. 7, 1966, pages 78 - 80 * |
See also references of WO9210999A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0644754A1 (en) | 1995-03-29 |
AU9103491A (en) | 1992-07-22 |
AU662505B2 (en) | 1995-09-07 |
CA2095439C (en) | 1998-12-08 |
WO1992010999A1 (en) | 1992-07-09 |
CA2095439A1 (en) | 1992-06-07 |
NO930858D0 (en) | 1993-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Erichsen | The Science and Art of Surgery... | |
KR101283820B1 (en) | Oral compositions for absorption of phosphorus compounds | |
EP0727985A1 (en) | Composition and method for treating blood vessel disorders of the skin using vitamin k | |
US6455067B1 (en) | Transdermal patch for nonsteroidal antiinflammatory drug(s) | |
Muir | Text-book of Pathology | |
US5230996A (en) | Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation | |
TWI287447B (en) | Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia | |
Ramasastry | Chronic problem wounds | |
WO1997039746A1 (en) | Method of and composition for treating disorders of the skin using vitamin k | |
JPH04149126A (en) | Pharmaceutical composition for transmucous administration | |
Sigurdsson et al. | Formic acid burn—Local and systemic effects Report of a case | |
AU662505B2 (en) | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes | |
CN104784193B (en) | Pharmaceutical application of protopanaxadiol type notoginsenoside | |
EP0532706B1 (en) | REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS | |
US5114974A (en) | Treatment of atherosclerosis with MgNa2 EDTA | |
US20040151769A1 (en) | Film coated tablet containing an extract of red vine leaves | |
Lee et al. | Hemostatic materials in non-variceal upper gastrointestinal hemorrhage | |
Lau et al. | Wound care in the elderly patient | |
AU2003298180A1 (en) | Film coated tablet comprising an extract of red vine leaves | |
Collings et al. | Three cases of inoculation of tuberculosis from tattooing | |
Clements | Manifestations of nutritional deficiency in infants | |
CA3073146C (en) | Use of 2-[(3z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1--yl] acetic acid for making a healing preparation for wounds in patients with diabetes | |
Chandler et al. | Benign duodeno-colonic fistula | |
Krishna | Study of Surgincal Complicatons in Diabetic Patients Among The Rural Population | |
Green | Pathology and morbid anatomy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19940428 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE DK ES FR GB IT LI LU MC NL SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19950626 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE |
|
17Q | First examination report despatched |
Effective date: 19980803 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 19980803 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
APAB | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPE |
|
APBX | Invitation to file observations in appeal sent |
Free format text: ORIGINAL CODE: EPIDOSNOBA2E |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
18D | Application deemed to be withdrawn |
Effective date: 20050701 |